O	0	7	Effects
O	8	10	of
B-intervention	11	19	exercise
O	20	26	during
O	27	35	adjuvant
O	36	48	chemotherapy
O	49	51	on
O	52	58	breast
O	59	65	cancer
O	66	74	outcomes
O	74	75	.

O	76	89	Observational
O	90	97	studies
O	98	105	suggest
O	106	110	that
O	111	119	physical
O	120	128	activity
O	129	134	after
O	135	136	a
O	137	143	breast
O	144	150	cancer
O	151	160	diagnosis
O	161	163	is
O	164	174	associated
O	175	179	with
O	180	188	improved
O	189	195	cancer
O	196	204	outcomes
O	204	205	;
O	206	213	however
O	213	214	,
O	215	217	no
O	218	228	randomized
O	229	233	data
O	234	237	are
O	238	247	available
O	247	248	.

O	249	253	Here
O	253	254	,
O	255	257	we
O	258	264	report
O	265	267	an
O	268	279	exploratory
O	280	286	follow
O	286	287	-
O	287	289	up
O	290	292	of
O	293	299	cancer
O	300	308	outcomes
O	309	313	from
O	314	317	the
O	318	328	Supervised
O	329	334	Trial
O	335	337	of
O	338	345	Aerobic
O	346	352	versus
O	353	363	Resistance
O	364	372	Training
O	373	374	(
O	374	379	START
O	379	380	)
O	380	381	.

O	382	385	The
O	386	391	START
O	392	395	was
O	396	397	a
B-location	398	406	Canadian
O	407	418	multicenter
O	419	424	trial
O	425	429	that
O	430	440	randomized
B-total-participants	441	444	242
O	445	451	breast
O	452	458	cancer
O	459	467	patients
O	468	475	between
O	476	480	2003
O	481	484	and
O	485	489	2005
O	490	492	to
B-control	493	498	usual
I-control	499	503	care
O	504	505	(
O	505	506	n
O	507	508	=
B-control-participants	509	511	82
O	511	512	)
O	512	513	,
O	514	524	supervised
O	525	532	aerobic
O	533	534	(
O	534	535	n
O	536	537	=
B-intervention-participants	538	540	78
O	540	541	)
O	541	542	,
O	543	545	or
O	546	556	resistance
O	557	558	(
O	558	559	n
O	560	561	=
B-intervention-participants	562	564	82
O	564	565	)
O	566	574	exercise
O	575	581	during
O	582	594	chemotherapy
O	594	595	.

O	596	599	The
O	600	607	primary
O	608	611	end
O	612	617	point
O	618	621	for
O	622	626	this
O	627	638	exploratory
O	639	647	analysis
O	648	651	was
B-outcome-Measure	652	659	disease
I-outcome-Measure	659	660	-
I-outcome-Measure	660	664	free
I-outcome-Measure	665	673	survival
I-outcome-Measure	674	675	(
I-outcome-Measure	675	678	DFS
I-outcome-Measure	678	679	)
O	679	680	.

O	681	690	Secondary
O	691	694	end
O	695	701	points
O	702	706	were
B-outcome-Measure	707	714	overall
I-outcome-Measure	715	723	survival
O	723	724	,
B-outcome-Measure	725	732	distant
I-outcome-Measure	733	736	DFS
O	736	737	,
O	738	741	and
B-outcome-Measure	742	752	recurrence
I-outcome-Measure	752	753	-
I-outcome-Measure	753	757	free
I-outcome-Measure	758	766	interval
O	766	767	.

O	768	771	The
O	772	775	two
O	776	784	exercise
O	785	789	arms
O	790	794	were
O	795	803	combined
O	804	807	for
O	808	816	analysis
O	817	818	(
O	818	819	n
O	820	821	=
B-intervention-participants	822	825	160
O	825	826	)
O	826	827	,
O	828	831	and
O	832	840	selected
O	841	850	subgroups
O	851	855	were
O	856	864	explored
O	864	865	.

O	866	871	After
O	872	873	a
O	874	880	median
O	881	887	follow
O	887	888	-
O	888	890	up
O	891	893	of
O	894	896	89
O	897	903	months
O	903	904	,
O	905	910	there
O	911	915	were
B-iv-bin-abs	916	918	25
O	918	919	/
B-intervention-participants	919	922	160
O	923	924	(
B-iv-bin-percent	924	926	15
I-iv-bin-percent	926	927	.
I-iv-bin-percent	927	928	6
I-iv-bin-percent	928	929	%
O	929	930	)
B-outcome	931	934	DFS
I-outcome	935	941	events
O	942	944	in
O	945	948	the
O	949	957	exercise
O	958	964	groups
O	965	968	and
B-cv-bin-abs	969	971	18
O	971	972	/
B-control-participants	972	974	82
O	975	976	(
B-cv-bin-percent	976	978	22
I-cv-bin-percent	978	979	.
I-cv-bin-percent	979	980	0
I-cv-bin-percent	980	981	%
O	981	982	)
O	983	985	in
O	986	989	the
O	990	997	control
O	998	1003	group
O	1003	1004	.

B-outcome	1005	1010	Eight
I-outcome	1010	1011	-
I-outcome	1011	1015	year
I-outcome	1016	1019	DFS
O	1020	1023	was
B-iv-bin-percent	1024	1026	82
I-iv-bin-percent	1026	1027	.
I-iv-bin-percent	1027	1028	7
I-iv-bin-percent	1028	1029	%
O	1030	1033	for
O	1034	1037	the
O	1038	1046	exercise
O	1047	1053	groups
O	1054	1062	compared
O	1063	1067	with
B-cv-bin-percent	1068	1070	75
I-cv-bin-percent	1070	1071	.
I-cv-bin-percent	1071	1072	6
I-cv-bin-percent	1072	1073	%
O	1074	1077	for
O	1078	1081	the
O	1082	1089	control
O	1090	1095	group
O	1096	1097	(
O	1097	1099	HR
O	1099	1100	,
O	1101	1102	0
O	1102	1103	.
O	1103	1105	68
O	1105	1106	;
O	1107	1109	95
O	1109	1110	%
O	1111	1121	confidence
O	1122	1130	interval
O	1131	1132	(
O	1132	1134	CI
O	1134	1135	)
O	1135	1136	,
O	1137	1138	0
O	1138	1139	.
O	1139	1141	37
O	1141	1142	-
O	1142	1143	1
O	1143	1144	.
O	1144	1146	24
O	1146	1147	;
O	1148	1151	log
O	1151	1152	-
O	1152	1156	rank
O	1156	1157	,
O	1158	1159	P
O	1160	1161	=
O	1162	1163	0
O	1163	1164	.
O	1164	1166	21
O	1166	1167	)
O	1167	1168	.

O	1169	1177	Slightly
O	1178	1186	stronger
O	1187	1194	effects
O	1195	1199	were
O	1200	1208	observed
O	1209	1212	for
B-outcome	1213	1220	overall
I-outcome	1221	1229	survival
O	1230	1231	(
O	1231	1233	HR
O	1233	1234	,
O	1235	1236	0
O	1236	1237	.
O	1237	1239	60
O	1239	1240	;
O	1241	1243	95
O	1243	1244	%
O	1245	1247	CI
O	1247	1248	,
O	1249	1250	0
O	1250	1251	.
O	1251	1253	27
O	1253	1254	-
O	1254	1255	1
O	1255	1256	.
O	1256	1258	33
O	1258	1259	;
O	1260	1263	log
O	1263	1264	-
O	1264	1268	rank
O	1268	1269	,
O	1270	1271	P
O	1272	1273	=
O	1274	1275	0
O	1275	1276	.
O	1276	1278	21
O	1278	1279	)
O	1279	1280	,
B-outcome	1281	1288	distant
I-outcome	1289	1292	DFS
O	1293	1294	(
O	1294	1296	HR
O	1296	1297	,
O	1298	1299	0
O	1299	1300	.
O	1300	1302	62
O	1302	1303	;
O	1304	1306	95
O	1306	1307	%
O	1308	1310	CI
O	1310	1311	,
O	1312	1313	0
O	1313	1314	.
O	1314	1316	32
O	1316	1317	-
O	1317	1318	1
O	1318	1319	.
O	1319	1321	19
O	1321	1322	;
O	1323	1326	log
O	1326	1327	-
O	1327	1331	rank
O	1331	1332	,
O	1333	1334	P
O	1335	1336	=
O	1337	1338	0
O	1338	1339	.
O	1339	1341	15
O	1341	1342	)
O	1342	1343	,
O	1344	1347	and
B-outcome	1348	1358	recurrence
I-outcome	1358	1359	-
I-outcome	1359	1363	free
I-outcome	1364	1372	interval
O	1373	1374	(
O	1374	1376	HR
O	1376	1377	,
O	1378	1379	0
O	1379	1380	.
O	1380	1382	58
O	1382	1383	;
O	1384	1386	95
O	1386	1387	%
O	1388	1390	CI
O	1390	1391	,
O	1392	1393	0
O	1393	1394	.
O	1394	1396	30
O	1396	1397	-
O	1397	1398	1
O	1398	1399	.
O	1399	1401	11
O	1401	1402	;
O	1403	1407	Gray
O	1408	1412	test
O	1412	1413	,
O	1414	1415	P
O	1416	1417	=
O	1418	1419	0
O	1419	1420	.
O	1420	1423	095
O	1423	1424	)
O	1424	1425	.

O	1426	1434	Subgroup
O	1435	1443	analyses
O	1444	1453	suggested
O	1454	1465	potentially
O	1466	1474	stronger
O	1475	1483	exercise
O	1484	1491	effects
O	1492	1494	on
B-outcome	1495	1498	DFS
O	1499	1502	for
B-outcome	1503	1508	women
I-outcome	1509	1512	who
I-outcome	1513	1517	were
I-outcome	1518	1528	overweight
I-outcome	1528	1529	/
I-outcome	1529	1534	obese
O	1535	1536	(
O	1536	1538	HR
O	1538	1539	,
O	1540	1541	0
O	1541	1542	.
O	1542	1544	59
O	1544	1545	;
O	1546	1548	95
O	1548	1549	%
O	1550	1552	CI
O	1552	1553	,
O	1554	1555	0
O	1555	1556	.
O	1556	1558	27
O	1558	1559	-
O	1559	1560	1
O	1560	1561	.
O	1561	1563	27
O	1563	1564	)
O	1564	1565	,
O	1566	1569	had
B-outcome	1570	1575	stage
I-outcome	1576	1578	II
I-outcome	1578	1579	/
I-outcome	1579	1582	III
I-outcome	1583	1589	cancer
O	1590	1591	(
O	1591	1593	HR
O	1593	1594	,
O	1595	1596	0
O	1596	1597	.
O	1597	1599	61
O	1599	1600	;
O	1601	1603	95
O	1603	1604	%
O	1605	1607	CI
O	1607	1608	,
O	1609	1610	0
O	1610	1611	.
O	1611	1613	31
O	1613	1614	-
O	1614	1615	1
O	1615	1616	.
O	1616	1618	20
O	1618	1619	)
O	1619	1620	,
B-outcome	1621	1629	estrogen
I-outcome	1630	1638	receptor
I-outcome	1638	1639	-
I-outcome	1639	1647	positive
I-outcome	1648	1654	tumors
O	1655	1656	(
O	1656	1658	HR
O	1658	1659	,
O	1660	1661	0
O	1661	1662	.
O	1662	1664	58
O	1664	1665	;
O	1666	1668	95
O	1668	1669	%
O	1670	1672	CI
O	1672	1673	,
O	1674	1675	0
O	1675	1676	.
O	1676	1678	26
O	1678	1679	-
O	1679	1680	1
O	1680	1681	.
O	1681	1683	29
O	1683	1684	)
O	1684	1685	,
B-outcome	1686	1691	human
I-outcome	1692	1701	epidermal
I-outcome	1702	1708	growth
I-outcome	1709	1715	factor
I-outcome	1716	1724	receptor
I-outcome	1725	1726	2
I-outcome	1726	1727	-
I-outcome	1727	1735	positive
I-outcome	1736	1742	tumors
O	1743	1744	(
O	1744	1746	HR
O	1746	1747	,
O	1748	1749	0
O	1749	1750	.
O	1750	1752	21
O	1752	1753	;
O	1754	1756	95
O	1756	1757	%
O	1758	1760	CI
O	1760	1761	,
O	1762	1763	0
O	1763	1764	.
O	1764	1766	04
O	1766	1767	-
O	1767	1768	1
O	1768	1769	.
O	1769	1771	02
O	1771	1772	)
O	1772	1773	,
B-outcome	1774	1782	received
I-outcome	1783	1789	taxane
I-outcome	1789	1790	-
I-outcome	1790	1795	based
I-outcome	1796	1810	chemotherapies
O	1811	1812	(
O	1812	1814	HR
O	1814	1815	,
O	1816	1817	0
O	1817	1818	.
O	1818	1820	46
O	1820	1821	;
O	1822	1824	95
O	1824	1825	%
O	1826	1828	CI
O	1828	1829	,
O	1830	1831	0
O	1831	1832	.
O	1832	1834	19
O	1834	1835	-
O	1835	1836	1
O	1836	1837	.
O	1837	1839	15
O	1839	1840	)
O	1840	1841	,
O	1842	1845	and
O	1846	1847	â
O	1847	1848	‰
O	1848	1849	¥
O	1849	1851	85
O	1851	1852	%
O	1853	1855	of
O	1856	1861	their
B-outcome	1862	1869	planned
I-outcome	1870	1882	chemotherapy
O	1883	1884	(
O	1884	1886	HR
O	1886	1887	,
O	1888	1889	0
O	1889	1890	.
O	1890	1892	50
O	1892	1893	;
O	1894	1896	95
O	1896	1897	%
O	1898	1900	CI
O	1900	1901	,
O	1902	1903	0
O	1903	1904	.
O	1904	1906	25
O	1906	1907	-
O	1907	1908	1
O	1908	1909	.
O	1909	1911	01
O	1911	1912	)
O	1912	1913	.

O	1914	1918	This
O	1919	1930	exploratory
O	1931	1937	follow
O	1937	1938	-
O	1938	1940	up
O	1941	1943	of
O	1944	1947	the
O	1948	1953	START
O	1954	1962	provides
O	1963	1966	the
O	1967	1972	first
O	1973	1983	randomized
O	1984	1988	data
O	1989	1991	to
O	1992	1999	suggest
O	2000	2004	that
O	2005	2011	adding
O	2012	2020	exercise
O	2021	2023	to
O	2024	2032	standard
O	2033	2045	chemotherapy
O	2046	2049	may
O	2050	2057	improve
O	2058	2064	breast
O	2065	2071	cancer
O	2072	2080	outcomes
O	2080	2081	.

O	2082	2083	A
O	2084	2094	definitive
O	2095	2100	phase
O	2101	2104	III
O	2105	2110	trial
O	2111	2113	is
O	2114	2123	warranted
O	2123	2124	.
